TMPA

TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation[1][2].

Product Specifications

CAS Number

[1258275-73-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

AMPK; Nuclear Hormone Receptor 4A/NR4A

Type

Reference compound

Related Pathways

Epigenetics; PI3K/Akt/mTOR; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/TMPA.html

Purity

98.40

Solubility

DMSO : ≥ 100 mg/mL

Smiles

COC1=C(CC(OCC)=O)C(C(CCCCCCC)=O)=CC(OC)=C1OC

Molecular Formula

C21H32O6

Molecular Weight

380.48

Precautions

H302, H315, H319

References & Citations

[1]Zhan YY, et al. The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat Chem Biol. 2012 Nov;8 (11) :897-904. |[2]Recher, et al. Modulation of T-cell apoptosis by small molecule compounds targeting the nuclear orphan receptor Nur 77. (2018) .